The Experts below are selected from a list of 324 Experts worldwide ranked by ideXlab platform

F. C. J. Van Neer - One of the best experts on this subject based on the ideXlab platform.

  • Itraconazole in the treatment of Tinea pedis and Tinea Manuum: comparison of two treatment schedules: Itraconazol bei der Behandlung der Tinea pedis und Tinea Manuum: Vergleich zweier Behandlungsschemata
    Mycoses, 2008
    Co-Authors: J. Schuller, J. J. Remme, F. H. J. Rampen, F. C. J. Van Neer
    Abstract:

    A multicentre, randomized, double-blind, parallel-group trial was conducted to compare the efficacy and safety of two dosages of itraconazole in the treatment of Tinea pedis or Manuum. Of the 135 patients recruited, 66 received itraconazole 400 mg daily for 1 week and 69 received itraconazole 100 mg daily for 4 weeks. In the evaluable patients observed-case analysis, mycological cure was seen in 63% of patients in the 400 mg/1 week group and in 75% in the 100 mg/4 weeks group at the end of a 6-week follow-up period (not significantly equivalent). In the evaluable patients worst-case analysis and the intention-to-treat analysis, mycological cure rates in the two groups were borderline significantly equivalent at the end of follow-up (range 51-57%). Clinical response was seen in 81% of evaluable patients in the 400 mg/1 week group and in 75% in the 100 mg/4 weeks group at the end of follow-up; equivalence testing showed the 400 mg/1 week regimen to be at least equivalent to the 100 mg/4 week regimen. Similar results were found in the intention-to-treat analysis, and tolerability ratings for the two treatment regimens were significantly equivalent. This trial has shown that itraconazole 400 mg/1 week and itraconazole 100 mg/4 weeks are both effective regimens for the treatment of Tinea pedis or Manuum. The two treatment schedules were equally well tolerated and safe.

  • itraconazole in the treatment of Tinea pedis and Tinea Manuum comparison of two treatment schedules itraconazol bei der behandlung der Tinea pedis und Tinea Manuum vergleich zweier behandlungsschemata
    Mycoses, 2008
    Co-Authors: J. Schuller, J. J. Remme, F. H. J. Rampen, F. C. J. Van Neer
    Abstract:

    Summary. A multicentre, randomized, doubleblind, parallel-group trial was conducted to compare the efficacy and safety of two dosages of itraconazole in the treatment of Tinea pedis or Manuum. Of the 135 patients recruited, 66 received itraconazole 400 mg daily for 1 week and 69 received itraconazole 100 mg daily for 4 weeks. In the evaluable patients observed-case analysis, mycological cure was seen in 63% of patients in the 400 mg/1 week group and in 75% in the 100 mg/4 weeks group at the end of a 6-week follow-up period (not significantly equivalent). In the evaluable patients worst-case analysis and the intention-to-treat analysis, mycological cure rates in the two groups were borderline significantly equivalent at the end of follow-up (range 51–57%). Clinical response was seen in 81% of evaluable patients in the 400 mg/1 week group and in 75% in the 100 mg/4 weeks group at the end of follow-up; equivalence testing showed the 400 mg/1 week regimen to be at least equivalent to the 100 mg/4 week regimen. Similar results were found in the intention-to-treat analysis, and tolerability ratings for the two treatment regimens were significantly equivalent. This trial has shown that itraconazole 400 mg/1 week and itraconazole 100 mg/4 weeks are both effective regimens for the treatment of Tinea pedis or Manuum. The two treatment schedules were equally well tolerated and safe. Zusammenfassung. Zum Vergleich der Wirksamkeit und Sicherheit von zwei Itraconazol-Dosierungen bei der Behandlung der Tinea pedis oder Manuum wurde eine randomisierte, doppelblinde Multicentre-Parallelgruppenstudie durchgefuhrt. Von den 135 Patienten wurden 66 Patienten 1 Woche lang mit 400 mg Itraconazol taglich und 69 Patienten 4 Wochen lang mit 100 mg Itraconazol taglich behandelt. Bei der Observed-case-Analyse der evaluierbaren Patienten wurde bei der Nachuntersuchung nach 6 Wochen bei 63% der Patienten der Gruppe mit 400 mg/1 Woche und 75% der Patienten der Gruppe mit 100 mg/4 Wochen eine mykologische Heilung festgestellt (nicht signifikant aquivalent). In der Worst-case-Analyse der evaluierbaren Patienten und der Intention-to-treat-Analyse waren die mykologischen Heilungsergebnisse bei der Nachuntersuchung grenzwertig signifikant aquivalent (51–57%). Bei der Nachuntersuchung wurde bei 81% der evaluierbaren Patienten der Gruppe mit 400 mg/1 Woche und bei 75% der Gruppe mit 100 mg/4 Wochen ein klinischer Respons beobachtet. Aquivalenztests ergaben, das die Behandlungsplane mindestens aquivalent waren. Die Intention-to-treat-Analyse fuhrte zu ahnlichen Ergebnissen, und die Vertraglichkeitsbewertung war bei beiden Therapien signifikant aquivalent. Diese Studie ergab, das Itraconazol 400 mg/1 Woche und Itraconazol 100 mg/4 Wochen wirksame Therapien fur die Tinea pedis oder Manuum sind. Beide Behandlungsschemata sind gleich gut vertraglich und sicher.

J. Schuller - One of the best experts on this subject based on the ideXlab platform.

  • Itraconazole in the treatment of Tinea pedis and Tinea Manuum: comparison of two treatment schedules: Itraconazol bei der Behandlung der Tinea pedis und Tinea Manuum: Vergleich zweier Behandlungsschemata
    Mycoses, 2008
    Co-Authors: J. Schuller, J. J. Remme, F. H. J. Rampen, F. C. J. Van Neer
    Abstract:

    A multicentre, randomized, double-blind, parallel-group trial was conducted to compare the efficacy and safety of two dosages of itraconazole in the treatment of Tinea pedis or Manuum. Of the 135 patients recruited, 66 received itraconazole 400 mg daily for 1 week and 69 received itraconazole 100 mg daily for 4 weeks. In the evaluable patients observed-case analysis, mycological cure was seen in 63% of patients in the 400 mg/1 week group and in 75% in the 100 mg/4 weeks group at the end of a 6-week follow-up period (not significantly equivalent). In the evaluable patients worst-case analysis and the intention-to-treat analysis, mycological cure rates in the two groups were borderline significantly equivalent at the end of follow-up (range 51-57%). Clinical response was seen in 81% of evaluable patients in the 400 mg/1 week group and in 75% in the 100 mg/4 weeks group at the end of follow-up; equivalence testing showed the 400 mg/1 week regimen to be at least equivalent to the 100 mg/4 week regimen. Similar results were found in the intention-to-treat analysis, and tolerability ratings for the two treatment regimens were significantly equivalent. This trial has shown that itraconazole 400 mg/1 week and itraconazole 100 mg/4 weeks are both effective regimens for the treatment of Tinea pedis or Manuum. The two treatment schedules were equally well tolerated and safe.

  • itraconazole in the treatment of Tinea pedis and Tinea Manuum comparison of two treatment schedules itraconazol bei der behandlung der Tinea pedis und Tinea Manuum vergleich zweier behandlungsschemata
    Mycoses, 2008
    Co-Authors: J. Schuller, J. J. Remme, F. H. J. Rampen, F. C. J. Van Neer
    Abstract:

    Summary. A multicentre, randomized, doubleblind, parallel-group trial was conducted to compare the efficacy and safety of two dosages of itraconazole in the treatment of Tinea pedis or Manuum. Of the 135 patients recruited, 66 received itraconazole 400 mg daily for 1 week and 69 received itraconazole 100 mg daily for 4 weeks. In the evaluable patients observed-case analysis, mycological cure was seen in 63% of patients in the 400 mg/1 week group and in 75% in the 100 mg/4 weeks group at the end of a 6-week follow-up period (not significantly equivalent). In the evaluable patients worst-case analysis and the intention-to-treat analysis, mycological cure rates in the two groups were borderline significantly equivalent at the end of follow-up (range 51–57%). Clinical response was seen in 81% of evaluable patients in the 400 mg/1 week group and in 75% in the 100 mg/4 weeks group at the end of follow-up; equivalence testing showed the 400 mg/1 week regimen to be at least equivalent to the 100 mg/4 week regimen. Similar results were found in the intention-to-treat analysis, and tolerability ratings for the two treatment regimens were significantly equivalent. This trial has shown that itraconazole 400 mg/1 week and itraconazole 100 mg/4 weeks are both effective regimens for the treatment of Tinea pedis or Manuum. The two treatment schedules were equally well tolerated and safe. Zusammenfassung. Zum Vergleich der Wirksamkeit und Sicherheit von zwei Itraconazol-Dosierungen bei der Behandlung der Tinea pedis oder Manuum wurde eine randomisierte, doppelblinde Multicentre-Parallelgruppenstudie durchgefuhrt. Von den 135 Patienten wurden 66 Patienten 1 Woche lang mit 400 mg Itraconazol taglich und 69 Patienten 4 Wochen lang mit 100 mg Itraconazol taglich behandelt. Bei der Observed-case-Analyse der evaluierbaren Patienten wurde bei der Nachuntersuchung nach 6 Wochen bei 63% der Patienten der Gruppe mit 400 mg/1 Woche und 75% der Patienten der Gruppe mit 100 mg/4 Wochen eine mykologische Heilung festgestellt (nicht signifikant aquivalent). In der Worst-case-Analyse der evaluierbaren Patienten und der Intention-to-treat-Analyse waren die mykologischen Heilungsergebnisse bei der Nachuntersuchung grenzwertig signifikant aquivalent (51–57%). Bei der Nachuntersuchung wurde bei 81% der evaluierbaren Patienten der Gruppe mit 400 mg/1 Woche und bei 75% der Gruppe mit 100 mg/4 Wochen ein klinischer Respons beobachtet. Aquivalenztests ergaben, das die Behandlungsplane mindestens aquivalent waren. Die Intention-to-treat-Analyse fuhrte zu ahnlichen Ergebnissen, und die Vertraglichkeitsbewertung war bei beiden Therapien signifikant aquivalent. Diese Studie ergab, das Itraconazol 400 mg/1 Woche und Itraconazol 100 mg/4 Wochen wirksame Therapien fur die Tinea pedis oder Manuum sind. Beide Behandlungsschemata sind gleich gut vertraglich und sicher.

S. Krajden - One of the best experts on this subject based on the ideXlab platform.

  • Onychomycosis, Tinea Pedis and Tinea Manuum Caused by Non‐Dermatophytic Filamentous Fungi Nicht‐Dermatophyten‐Fadenpilze als Erreger von Onychomykosen, Tinea pedis und Tinea Manuum
    Mycoses, 2009
    Co-Authors: Richard C. Summerbell, J. Kane, S. Krajden
    Abstract:

    Over 4000 cases of fungal nail, sole and palm infection recorded during a three-year study period were investigated to determine the prevalence and significance of etiologic agents other than dermatophytes and yeasts. Littman's oxgall agar, which permitted isolation of cycloheximide-sensitive species but restricted overgrowth by fast growing contaminants, was used to promote isolation of these disease agents. Non-dermatophytic filamentous fungi made up 2.3% of the confirmed etiologic agents obtained overall, and constituted 3.3% of the agents obtained from nail infections. The most common species were Scopulariopsis brevicaulis, Hendersonula toruloidea, and Aspergillus sydowii. Scytalidium hyalinum was recorded for the first time from Canada, and an instance of nail infection by Gymnascella dankaliensis was recorded. Only H. toruloidea and Sc. hyalinum caused palm and sole infections.

  • onychomycosis Tinea pedis and Tinea Manuum caused by non dermatophytic filamentous fungi nicht dermatophyten fadenpilze als erreger von onychomykosen Tinea pedis und Tinea Manuum
    Mycoses, 2009
    Co-Authors: Richard C. Summerbell, J. Kane, S. Krajden
    Abstract:

    Over 4000 cases of fungal nail, sole and palm infection recorded during a three-year study period were investigated to determine the prevalence and significance of etiologic agents other than dermatophytes and yeasts. Littman's oxgall agar, which permitted isolation of cycloheximide-sensitive species but restricted overgrowth by fast growing contaminants, was used to promote isolation of these disease agents. Non-dermatophytic filamentous fungi made up 2.3% of the confirmed etiologic agents obtained overall, and constituted 3.3% of the agents obtained from nail infections. The most common species were Scopulariopsis brevicaulis, Hendersonula toruloidea, and Aspergillus sydowii. Scytalidium hyalinum was recorded for the first time from Canada, and an instance of nail infection by Gymnascella dankaliensis was recorded. Only H. toruloidea and Sc. hyalinum caused palm and sole infections.

Jong Soo Choi - One of the best experts on this subject based on the ideXlab platform.

  • A case of Tinea Manuum caused by Trichophyton mentagrophytes var. erinacei: the first isolation in Korea
    Mycoses, 2008
    Co-Authors: Do-young Rhee, Sung-eun Chang, Mi-woo Lee, Jee-ho Choi, Kee-chan Moon, Myoung-shin Kim, Jai-kyoung Koh, Jong Soo Choi
    Abstract:

    Hedgehogs have recently become popular exotic pets in Korea. Several diseases may be acquired from these animals including dermatophytosis, Salmonella infections, contact urticaria and possibly Mycobacterium infections. We describe here a 15-year-old girl who developed Tinea Manuum after keeping a hedgehog for 4 months. Diagnosis was confirmed by histopathologic and mycological examination. The causative agent was identified as Trichophyton mentagrophytes var. erinacei, a zoophilic dermatophyte.

J. J. Remme - One of the best experts on this subject based on the ideXlab platform.

  • Itraconazole in the treatment of Tinea pedis and Tinea Manuum: comparison of two treatment schedules: Itraconazol bei der Behandlung der Tinea pedis und Tinea Manuum: Vergleich zweier Behandlungsschemata
    Mycoses, 2008
    Co-Authors: J. Schuller, J. J. Remme, F. H. J. Rampen, F. C. J. Van Neer
    Abstract:

    A multicentre, randomized, double-blind, parallel-group trial was conducted to compare the efficacy and safety of two dosages of itraconazole in the treatment of Tinea pedis or Manuum. Of the 135 patients recruited, 66 received itraconazole 400 mg daily for 1 week and 69 received itraconazole 100 mg daily for 4 weeks. In the evaluable patients observed-case analysis, mycological cure was seen in 63% of patients in the 400 mg/1 week group and in 75% in the 100 mg/4 weeks group at the end of a 6-week follow-up period (not significantly equivalent). In the evaluable patients worst-case analysis and the intention-to-treat analysis, mycological cure rates in the two groups were borderline significantly equivalent at the end of follow-up (range 51-57%). Clinical response was seen in 81% of evaluable patients in the 400 mg/1 week group and in 75% in the 100 mg/4 weeks group at the end of follow-up; equivalence testing showed the 400 mg/1 week regimen to be at least equivalent to the 100 mg/4 week regimen. Similar results were found in the intention-to-treat analysis, and tolerability ratings for the two treatment regimens were significantly equivalent. This trial has shown that itraconazole 400 mg/1 week and itraconazole 100 mg/4 weeks are both effective regimens for the treatment of Tinea pedis or Manuum. The two treatment schedules were equally well tolerated and safe.

  • itraconazole in the treatment of Tinea pedis and Tinea Manuum comparison of two treatment schedules itraconazol bei der behandlung der Tinea pedis und Tinea Manuum vergleich zweier behandlungsschemata
    Mycoses, 2008
    Co-Authors: J. Schuller, J. J. Remme, F. H. J. Rampen, F. C. J. Van Neer
    Abstract:

    Summary. A multicentre, randomized, doubleblind, parallel-group trial was conducted to compare the efficacy and safety of two dosages of itraconazole in the treatment of Tinea pedis or Manuum. Of the 135 patients recruited, 66 received itraconazole 400 mg daily for 1 week and 69 received itraconazole 100 mg daily for 4 weeks. In the evaluable patients observed-case analysis, mycological cure was seen in 63% of patients in the 400 mg/1 week group and in 75% in the 100 mg/4 weeks group at the end of a 6-week follow-up period (not significantly equivalent). In the evaluable patients worst-case analysis and the intention-to-treat analysis, mycological cure rates in the two groups were borderline significantly equivalent at the end of follow-up (range 51–57%). Clinical response was seen in 81% of evaluable patients in the 400 mg/1 week group and in 75% in the 100 mg/4 weeks group at the end of follow-up; equivalence testing showed the 400 mg/1 week regimen to be at least equivalent to the 100 mg/4 week regimen. Similar results were found in the intention-to-treat analysis, and tolerability ratings for the two treatment regimens were significantly equivalent. This trial has shown that itraconazole 400 mg/1 week and itraconazole 100 mg/4 weeks are both effective regimens for the treatment of Tinea pedis or Manuum. The two treatment schedules were equally well tolerated and safe. Zusammenfassung. Zum Vergleich der Wirksamkeit und Sicherheit von zwei Itraconazol-Dosierungen bei der Behandlung der Tinea pedis oder Manuum wurde eine randomisierte, doppelblinde Multicentre-Parallelgruppenstudie durchgefuhrt. Von den 135 Patienten wurden 66 Patienten 1 Woche lang mit 400 mg Itraconazol taglich und 69 Patienten 4 Wochen lang mit 100 mg Itraconazol taglich behandelt. Bei der Observed-case-Analyse der evaluierbaren Patienten wurde bei der Nachuntersuchung nach 6 Wochen bei 63% der Patienten der Gruppe mit 400 mg/1 Woche und 75% der Patienten der Gruppe mit 100 mg/4 Wochen eine mykologische Heilung festgestellt (nicht signifikant aquivalent). In der Worst-case-Analyse der evaluierbaren Patienten und der Intention-to-treat-Analyse waren die mykologischen Heilungsergebnisse bei der Nachuntersuchung grenzwertig signifikant aquivalent (51–57%). Bei der Nachuntersuchung wurde bei 81% der evaluierbaren Patienten der Gruppe mit 400 mg/1 Woche und bei 75% der Gruppe mit 100 mg/4 Wochen ein klinischer Respons beobachtet. Aquivalenztests ergaben, das die Behandlungsplane mindestens aquivalent waren. Die Intention-to-treat-Analyse fuhrte zu ahnlichen Ergebnissen, und die Vertraglichkeitsbewertung war bei beiden Therapien signifikant aquivalent. Diese Studie ergab, das Itraconazol 400 mg/1 Woche und Itraconazol 100 mg/4 Wochen wirksame Therapien fur die Tinea pedis oder Manuum sind. Beide Behandlungsschemata sind gleich gut vertraglich und sicher.